Two reconstruction options are routinely discussed following mastectomy in breast cancer: silicon implants or myocutaneous flaps. Recurring breast cancers have already been described within trans rectus abdominis muscle flaps (TRAM flaps). We here report the first case of breast cancer recurrence within a deep inferior epigastric posterior flap (DIEP flap) and discuss the potential of MRI in assessing the extent of recurrence within myocutaneous flaps.

The Breast JournalVolume 8, Issue 2 p. 117-118 Breast Lipoma Youlia M. Kirova MD, Corresponding Author Youlia M. Kirova MDAddress correspondence and reprint requests to: Youlia M. Kirova, MD, Department of Cancerology, Henri Mondor University Hospital, 51, av. du Mal de Lattre de Tassigny, 94010 Cŕeteil, France.Search for more papers by this authorFrank Feuilhade MD, PhD, Frank Feuilhade MD, PhD Department of Cancerology, Henri Mondor University Hospital, Cŕeteil, FranceSearch for more papers by this authorJean-Paul Le Bourgeois MD, Jean-Paul Le Bourgeois MD Department of Cancerology, Henri Mondor University Hospital, Cŕeteil, FranceSearch for more papers by this author Youlia M. Kirova MD, Corresponding Author Youlia M. Kirova MDAddress correspondence and reprint requests to: Youlia M. Kirova, MD, Department of Cancerology, Henri Mondor University Hospital, 51, av. du Mal de Lattre de Tassigny, 94010 Cŕeteil, France.Search for more papers by this authorFrank Feuilhade MD, PhD, Frank Feuilhade MD, PhD Department of Cancerology, Henri Mondor University Hospital, Cŕeteil, FranceSearch for more papers by this authorJean-Paul Le Bourgeois MD, Jean-Paul Le Bourgeois MD Department of Cancerology, Henri Mondor University Hospital, Cŕeteil, FranceSearch for more papers by this author First published: 22 September 2008 https://doi.org/10.1046/j.1524-4741.2002.08210.xCitations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume8, Issue2March/April 2002Pages 117-118 RelatedInformation

Between December 1982 and October 1986, 131 patients with stage II-III-IV squamous cell carcinoma of the oropharynx or oral cavity were randomized to induction chemotherapy, consisting of bleomycin (10 mg/m2/day in continuous infusion from day 1 to day 5), methotrexate (120 mg/m2 on day 2) followed by folinic acid, 5-fluorouracil (5 FU) (600 mg/m2 on day 2), and cisplatin (120 mg/m2 on day 4) every 4 weeks for a total of three cycles followed by definitive locoregional treatment versus locoregional treatment alone. The modalities of definitive treatment (radiotherapy +/- surgery) were chosen prior to randomization. A total of 116 patients were evaluable. Of 55 patients in the chemotherapy arm, four (7%) had a complete response (CR) and 23 (42%) a partial response (PR) following the induction regimen. At the completion of locoregional treatment, 76% (42 of 55) of patients in the experimental group were in CR compared to 89% (54 of 61) in the control group. There was no difference in survival, cause-specific survival, and pattern of relapse between both groups. The median survival was 22 months in the chemotherapy group and 29 months in the control group. Responders to chemotherapy did not fare better than nonresponders. Chemotherapy-related toxicities were few and most of them related to cisplatin which was reduced to 100 mg/m2 for 35 patients. There were no treatment-related deaths and, in the experimental arm of the trial, no increased morbidity from locoregional treatment. This induction regimen does not offer any advantages over standard treatment.